Department of Public Health, Faculty of Health Science, Universitas Dian Nuswantoro, Semarang, Indonesia.
Medical Oncoligist-Hematologist Consultant, dr. Karyadi Hospital, Semarang, Indonesia.
Asian Pac J Cancer Prev. 2022 Dec 1;23(12):4169-4176. doi: 10.31557/APJCP.2022.23.12.4169.
Cancer is a non-communicable disease that accounts for 71% of deaths globally. The prevalence of people living with cancer in Indonesia increased from 1.4/1000 population (2013) to 1.8/1,000 population (2018). This study aims to evaluate usability, user experience, and user feedback on the use of the Oncodoc m-health application.
The research method uses mixed methods with a cross-sectional approach and online survey sampling techniques (677 respondents), in December 2021-January 2022 in Indonesia. The instruments used are the System Usability Scale and User Experience Questionnaire. The variables measured include the characteristics of respondents, usability, user experience, and responses to using applications qualitatively. Quantitative data were analysed descriptively and the User Experience Questionnaire's analysis tool. Qualitative data were analysed thematically.
Evaluation of the usability of Oncodoc's m-health application is in the "acceptable" category (70.88), and the adjective rating is in the "Good" category. Evaluations of the relative quality of user experience are in the "good" and "very good" types. The average user experience scale is (mean; SD): attractiveness (1.80; 0.99), perspicuity (1.82; 1.05), efficiency (1.78; 1.09), dependability (1.56; 1.01), stimulation (1.81; 1.06), and novelty (1.32; 1.10). The findings of this study are 1) the ability to accommodate user needs, 2) usage barriers, and 3) user expectations for the Oncodoc application.
Overall, the Oncodoc m-health application is acceptable to users. We recommend developing a cancer early detection application with an approach that refers to user needs for further research.
癌症是非传染性疾病,占全球死亡人数的 71%。印度尼西亚癌症患者的患病率从每 1000 人中有 1.4 人(2013 年)增加到每 1000 人中有 1.8 人(2018 年)。本研究旨在评估 Oncodoc 移动医疗应用程序的可用性、用户体验和用户反馈。
本研究采用混合方法,采用横断面方法和在线调查抽样技术(677 名受访者),于 2021 年 12 月至 2022 年 1 月在印度尼西亚进行。使用的工具包括系统可用性量表和用户体验问卷。测量的变量包括受访者特征、可用性、用户体验以及对应用程序使用的定性反馈。定量数据采用描述性分析和用户体验问卷分析工具进行分析。定性数据采用主题分析方法进行分析。
Oncodoc 移动医疗应用程序的可用性评估处于“可接受”类别(70.88),形容词评级处于“良好”类别。用户体验的相对质量评估处于“良好”和“非常好”类型。用户体验量表的平均(均值;标准差)为:吸引力(1.80;0.99)、清晰度(1.82;1.05)、效率(1.78;1.09)、可靠性(1.56;1.01)、刺激(1.81;1.06)和新颖性(1.32;1.10)。本研究的结果是:1)满足用户需求的能力;2)使用障碍;3)用户对 Oncodoc 应用程序的期望。
总体而言,Oncodoc 移动医疗应用程序受到用户的欢迎。我们建议开发一种癌症早期检测应用程序,方法是参考用户对进一步研究的需求。